EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing



Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing



Clinical Microbiology Reviews 19(2): 435-447



Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between in vitro activity and outcome from both in vivo and clinical studies.

(PDF emailed within 0-6 h: $19.90)

Accession: 012799242

Download citation: RISBibTeXText

PMID: 16614256

DOI: 10.1128/CMR.19.2.435-447.2006



Related references

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clinical Infectious Diseases 24(2): 235-247, 1997

Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagnostic Microbiology and Infectious Disease 77(1): 37-40, 2014

EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clinical Microbiology and Infection 22(6): 571.E1-4, 2016

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagnostic Microbiology and Infectious Disease 73(4): 365-368, 2012

Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clinical Microbiology and Infection 20(7): 698-705, 2015

Antifungal susceptibility testing of Candida tropicalis biofilms against fluconazole using calorimetric indicator resazurin. Indian Journal of Pathology & Microbiology 55(1): 72-74, 2012

Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22(2): 132-136, 1994

Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature. Journal of Medical Microbiology 56(Pt 7): 1003-1004, 2007

Correlation between CLSI, EUCAST and Etest methodologies for amphotericin B and fluconazole antifungal susceptibility testing of Candida spp. clinical isolates. Die Pharmazie 63(4): 286-289, 2008

Correlation between microdilution, Etest, and disk diffusion methods for antifungal susceptibility testing of fluconazole against Candida sp. blood isolates. Revista Da Sociedade Brasileira de Medicina Tropical 46(1): 106-107, 2013

Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Antimicrobial Agents and ChemoTherapy 55(4): 1794-1797, 2011

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. Journal of Clinical Microbiology 46(2): 551-559, 2007

Types of interpretive errors in susceptibility testing. Zone breakpoints for norfloxacin disk diffusion testing. Apmis 97(10): 941-948, 1989

Correlation between broth microdilution and disk diffusion methods for antifungal susceptibility testing of caspofungin, voriconazole, amphotericin B, itraconazole and fluconazole against Candida glabrata. Journal of Microbiological Methods 82(2): 136-140, 2010

Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints. Mycoses (): -, 2016